Clinical Trial Finder

Inclusion Criteria:

1. Age ≥ 18 years. 2. Patients with multiple myeloma with measurable lesions as assessed using the updated International Myeloma Working Group Response Criteria. 3. Multiple myeloma patients with central nervous system involvement (CNS-MM): the presence of plasma cells in the cerebrospinal fluid (CSF), and/or leptomeningeal, dural, or intraparenchymal involvement as assessed using imaging modalities (MRI, CT or PET-CT), and/or tissue biopsy; or eye involvement confirmed by ophthalmologists, with or without neurological symptoms. 4. ECOG ≤ 2, with expected survival of more than 3 months. 5. No active infectious diseases. 6. Major organs without serious organic diseases (except renal insufficiency caused by multiple myeloma). 7. Female patients are not during pregnancy or breastfeeding; fertile men or women agree to use appropriate methods of contraception 4 weeks before study treatment, during treatment and drug suspension, and within 4 weeks after the end of study treatment. 8. Be able to cooperate with study follow-up. Patients understand the disease characteristics and voluntarily join this study to receive treatments and study follow-ups. 9. Have signed informed consent. Informed consent was signed by the patient or by an immediate family member. Considering the patient 's condition, if the patient' s signature is unfavorable for disease treatment, the informed consent form should be signed by the legal guardian or the patient 's immediate family member.

Exclusion Criteria:

1. Patients with active hepatitis B (HBV), hepatitis C (HCV), and other acquired, congenital immunodeficiency diseases; 2. According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 5.0, baseline with grade 2 or higher peripheral neuropathy or neuralgia; 3. Severe thrombotic events before treatment; 4. Patients with uncontrolled or severe cardiovascular disease, including myocardial infarction within 6 months before enrollment, New York Heart Association (NYHA) defined grade III-IV heart failure, uncontrolled angina pectoris, clinically significant pericardial disease or cardiac amyloidosis; 5. Major surgery within 30 days before enrollment; 6. Epilepsy and dementia which requires drug treatment, and other mental disorders which cannot understand or follow the study protocol; 7. According to the protocol or the investigator 's judgment, any severe physical illness or mental illness may interfere with participation in this clinical study; 8. Drug abuse, medical, psychological or social conditions that may interfere with the participation of subjects in the study or evaluation of study results; 9. Patients who are receiving other experimental treatment; 10. Pregnant or lactating women; 11. Not suitable for enrollment per investigators' judgements.

This is a single-arm, open-label, multicenter, exploratory study. The study plans to enroll patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle. If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events.

Arms

Experimental: Selinexor, pomalidomide and dexamethasone

Patients diagnosed with multiple myeloma with CNS involvement to receive SPD treatment.

Interventions

Drug: - SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone

Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle. If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events.